Member Info for inanaco

trying to find a picture of how moditope engages https://en.wikipedia.org/wiki/Antigen-presenting_cell page 15 https://www.scancell.co.uk/file-manager/PDFs/scancell-presentation-feb18v2.pdf

Ray .. moditope does not produce antibodies ... scancell does not modify T cells Scancell in immunobody modifies an antibody to deliver the epitopes to the dendritic cells these program the specific high avidity t cells, its the way the antibody engages the DC which generates this high avidity which is under patent. Moditope is a peptide vaccine, as the modified Epitopes are so immunogenic no modification is needed of the T cells they are only primed differentiate format of TH1 pro inflammatory Its the third platform that the antibody itself becomes the killer

example .... theoretical physics produces results that have to be investigated, because the theory predicts Higgs Boson is a prime example ... now this CD4/cd8 interaction can be proven straight away by the mono therapy PD1 trials .. or are You Boom confident that they don't work ? In melanoma with keytruda. ? can you see the problem area you are getting into here ? if you consider it unproven and risky , because you then have a conflict with the existing patients that have responded with out the need for an adaptive response. ie no vaccine Have a serious think about this interaction then reply

These data support the hypothesis that the efficacy of vaccine-induced T cells can be augmented by anti-PD-1 therapy, thus mitigating the influence of an immunosuppressive microenvironment. The investigators concluded that these findings merit confirmation in a larger randomised trial which is being planned. its Not a Cancer/vaccine/PD1 """"specific"""" statement its a hypothesis on Process or have i missed something ??? this is the evidence that the predicted synergy is being proven ... and that synergy exists regardless, as long as your key parts are functioning ...

But i will leave on a positive note which is this post here ........... its devastating news for any party that wants to throw up Risk as a blanket message to this BB ..... You cannot reason against it.... """"These data support the hypothesis that the efficacy of vaccine-induced T cells can be augmented by anti-PD-1 therapy, thus mitigating the influence of an immunosuppressive microenvironment. The investigators concluded that these findings merit confirmation in a larger randomised trial which is being planned.""" proof of synergy .... = SCIB1 with Keytruda ... SCLPproven proofSat 18:28 The authors pointed out that the ORR of 36% in patients with oropharyngeal cancer compares favourably to the ORR of 16% demonstrated for nivolumab monotherapy in patients with p16-positive platin-refractory oropharyngeal cancer participating in the in Checkmate 141 study.1 These data support the hypothesis that the efficacy of vaccine-induced T cells can be augmented by anti-PD-1 therapy, thus mitigating the influence of an immunosuppressive microenvironment. The investigators concluded that these findings merit confirmation in a larger randomised trial which is being planned. http://www.esmo.org/Oncology-News/Combined-Therapy-with-Nivolumab-and-ISA-101-Vaccine-Results-in-Promising-Efficacy-in-HPV-positive-Oropharyngeal-Cancer Nivolumab = Opdiva Bristol-Myers Squibb PD-1 immuno-oncology treatment 2015 sales: $942 million 2020 sales: $8.4 billion It might seem remarkable that within in the next 5 years a brand-new drug would become the third bestselling med in the world, and soar from zero to $8.4 billion with breakneck speed. But then Bristol-Myers Squibb's ($BMY) Opdivo is turning out to be a remarkable drug.

my polite post to you questioning your claim of buying before the news broke, no mention by the way of the price strike SCLPRE: Moditope PatentMon 13:10 I dont wish to create yet more conflict C7 .. but are you sure you purchased Scancell before Moditope news Broke ? 15 August 2012 so these posts are not rubbish, the corresponding post will be in your history ...

But you just keep coming back ... with more false claims ... which for me are so easy to refute ... so here is one of your claims ... yet another unanswered post .. SCLPC7 you never repliedFri 10:45 This highlights perfectly what you do, now i never beat the drum on this, and let it slide, but you really should think now before you make up all these spurious claims to try and damage my credibility when the evidence is to the contrary. SCLPC718 May '18 """ and do not like being labelled or demonised for honesty especially by somebody who told me to put every penny i had into this at 35p!!!! """" those are your words show any post of mine today the "demonised" traders because your just making up stuff ... to suit what ever game your playing ..

Scancell is all about the science its an area that you cannot "dominate in" , and to be honest its all about factual, or trying to understand factual, you cannot create fake news about the science. I posted numerous posts which you have no responded to. Indeed you posted that TF and myself are not genuine posters and you would not answer. I will not be drawn in to this tit for tat, posts of mine have not been answered yet you blow up comments I made to Roses as a sign that I lie, it was an off the cuff comment back to roses, i did not look at your post to confirm word for word exactly what you said, because it carried the meaning in context. Now if you want a factual out right lie, your claim of buying prior to the moditope RNS was just that, you apologised after i pointed it out ... what if i had not ? yes folks would be left thinking you bought at 19p not 41p and your claim that i told you to go all in at 35p would look plausible ... but if you bought at 41p buying again at 35p would not be unreasonable So on the one hand your accepting my posts on the science with praise, on the other hand you are trying to undermine my posts by claiming i argue and refuse to accept the alternative view, even when the other party does not have the science based understanding to promote or reason that view. Then Claiming i go personal, I asked you and Roses to reprint those personal attacks, nothing forthcoming, yet you both attack at the personal level hypocrisy on all fronts. The problem is simple, you are using this BB as your Face Book Page Its not ......... its about Scancell which is a researched based organisation dedicated to pushing the boundary's on the science.

C7 .. you are intent on creating conflict your post clearly was sarcastic to Roses ... so spin it how ever you wish ATB

Scancell PD-1 immuno-oncology treatment 2015 sales: $942 million 2020 sales: $8.4 billion the difference is we can treat every cancer ......... with far greater efficacy ...

£8 a share ... ATB

The authors pointed out that the ORR of 36% in patients with oropharyngeal cancer compares favourably to the ORR of 16% demonstrated for nivolumab monotherapy in patients with p16-positive platin-refractory oropharyngeal cancer participating in the in Checkmate 141 study.1 These data support the hypothesis that the efficacy of vaccine-induced T cells can be augmented by anti-PD-1 therapy, thus mitigating the influence of an immunosuppressive microenvironment. The investigators concluded that these findings merit confirmation in a larger randomised trial which is being planned. http://www.esmo.org/Oncology-News/Combined-Therapy-with-Nivolumab-and-ISA-101-Vaccine-Results-in-Promising-Efficacy-in-HPV-positive-Oropharyngeal-Cancer Nivolumab = Opdiva Bristol-Myers Squibb PD-1 immuno-oncology treatment 2015 sales: $942 million 2020 sales: $8.4 billion It might seem remarkable that within in the next 5 years a brand-new drug would become the third bestselling med in the world, and soar from zero to $8.4 billion with breakneck speed. But then Bristol-Myers Squibb's ($BMY) Opdivo is turning out to be a remarkable drug.

if only ... the proven message needs to be proved ...

already proven .... scib1 induces High Avidity T cells in patients with clear therapeutic efficacy that efficacy induces Interferon gamma which induces solid cancers to up regulate PD1 ligand so combine PD1 to block that interaction allows your T cells to expand and kill and overcoming the cancers suppression the trial will prove that i agree, but surely its a nice feeling that all other research in this field by others validates this prognosis .. makes holding the share very easy

Folks reading this stuff might not have a clue what i am on about, but what the Scancell engagement to the immune system does via immunobody is quite unique even ISA pharma itself developed amplivant to influence its own cd4/cd8 vaccines our CD4 vaccine moditope just happened to be a perfect fit to stressing cancer by inducing inflammatory t cells by using that amplivant technology but lindy has not needed it with Immunobody ... itself generates those very specific High Avidity which is a natural response which the innate system rarely produces which is why you get the escape phase. wrong t cells, tired t cells, and t regulatory cells and the cancers ability to suppress, but also immune tolerance by deletion in early stage T cell production . so again read the report on ISA website about the science ... http://www.isa-pharma.com/product-pipeline/product-overview/myisa/ It is known today that concentrated antigen sources, such as synthetic long peptides, can sufficiently raise robust CD4+ and CD8+ T cell responses to eradicate cancer. However, for optimum immunotherapy results it is necessary to choose antigens that are unique to each cancer. In the case of virus-induced cancers, this criterion is met by virus-induced antigens. However, in non-viral cancers many antigens are shared by tumor cells and normal cells, albeit with different levels of expression. As T cells induced by these antigens rely on the T cell repertoire that remains after the induction of central immune tolerance in the thymus, the available repertoire is depleted of high-avidity T cells, resulting in sub optimal immune responses. does it not stand out ... """the available repertoire is depleted of high-avidity T cells, resulting in sub optimal immune responses"" so take out the natural selection and induce High Avidity .... balance restored Tick Tock ...

oncosec ... correct spell

because its only cancer specific and its the most direct way to induce the "correct" t cells without the use of separate immune modulators like the Interleukin family for instance il-12 (onconsec) basically they are trying to flip the environment to TH1 t cells which are pro inflammatory, immunobody already does this as witnessed in trial, so any modulation can affect all t cells not just the ones your targeting if its not combined into a specific targeted vaccine. Moditopes modulator is actually built into the vaccine as a single agent .. ISA adjuvant, amplivant but this is not about like il-12 improving the T cells its actually being used to flip the production of TH1 t cells from the start, ie your repertoire of t cells are TH1 positive rather than setting up for a more balanced Th1/Th2 response which is what you would have had in the first Modi1 The Th2-type cytokines include interleukins 4, 5, and 13, which are associated with the promotion of IgE and eosinophilic responses in atopy, and also interleukin-10, which has more of an anti-inflammatory response. In excess, Th2 responses will counteract the Th1 mediated microbicidal action. The optimal scenario would therefore seem to be that humans should produce a well balanced Th1 and Th2 response, suited to the immune challenge. do you remember the discussion on the TH1 ? when i was discussing scancell able to tune a vaccine to a target by flipping the type of response ie changing the balance of the CD4 ? so this is all about Direct targeting ... PD1 .. whole body experience Ctl4 whole body experience so any products that modulate the immune system can not be targeted that includes all the check point inhibitors so cytokines have a major effect across the board. highlighted by Car T ... CRS ... Cytokine release syndrome this time the immune system is driven into overdrive by the insertion of these modified T cells Immunobody targeted natural response Moditope targeted natural response flipped to TH1 production in modi1 hope that helps in the way i am thinking ...

invasive ... duh !

Ruckrover, sorry to hear about that, but yes, Scancells route to market is the least invasive procedure of all the immunotherapies, i would highlight something else PD1 has its known side effects, because of that, you want to see the highest patient "improvement" possible of the patients treated, but non res ponder are still having to go through the discomfort of the PD1 regime at least Scancells product range carries very little ongoing discomfort apart from the dreaded needle ... 1 or 2 seconds. Moditope will one day show that last resort "non evasive treatments" are possible and the word Cure is not far away.

problem is, we are so well versed on the science and the commercial aspects of scancell what alternative view can be reasoned ? ONW is trying to get across some alternative view, how is that going ? can you understand it ? the issue is more to do with the SP rather than the fundamentals of Scancell and that is sentiment driven which is also linked to understanding which also links to trading, nobody could argue the buyer wants it up, the seller wants it down to buy again which sets of an area of conflict as competing Views will clash .. thing is your perception of what the BB is can be easily misplaced unless you look at every post with an open mind and understanding of what the LTH or traders position is .. Cons work by manipulation .. you see it all the time by those that seek to play on parties trusting nature and BB's are no different because behind the facade lies Money